The new drug is an Allogeneic CAR-T Candidate for Relapsed/Refractory Multiple Myeloma... Sep 03
... Jun 25
... Dec 08
Antibody-Drug-Nanoparticle Albumin-Bound Immune Complex (ADNIC) platform exclusive license from Sorento... Sep 15
FDA approves GSK’s BLENREP (belantamab mafodotin-blmf) for the treatment of patients with relapsed or refractory multiple myeloma... Aug 07
Finally Bristol Myers Squib receives approval from EU for Idecabtagene Vicleucel... May 23
-Advertisements-